The line between educating healthcare professionals and wooing them can still be fuzzy, which is impacting what doctors ...
Despite an uptick in dealmaking and IPOs, a selective funding market and scientific setbacks are still pushing some biotechs ...
Drugmakers are pouring billions into U.S. production, but building enough plants won’t matter without enough skilled workers ...
Ai3Bio recently emerged from stealth with preclinical programs aimed at what it believes could be a root cause of autoimmune ...
A new report argues that more flexible eligibility criteria could widen pharma’s clinical trial pool without sacrificing ...
Attempting to bring new medicines to market is an inherently risky endeavor, with sponsors ultimately failing more than 90% of the time. But rare disease development is even harder; there are fewer ...
The FDA green-lit four drugs last year without any U.S. trial participants, according to CDER’s drug trials snapshot report, which summarizes the various demographics of clinical trials for approved ...
Job cuts continue to climb and pervade the biopharma sector this year, defying hopes that 2024 marked a peak. After shedding more than 14,000 jobs in all of 2024, the industry surpassed 13,000 layoffs ...
As patent protection for the cancer juggernaut Keytruda approaches a critical juncture, Merck & Co. won’t give up market share without a fight. The company revealed this week that a subcutaneous ...
CEOs can make or break a company. And new leaders at three of pharma’s largest drugmakers are taking over with little room for error. All three leaders took the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results